Opthea(OPT) - 2023 Q4 - Annual Report

Exhibit 99.1 QOPTHEA Hope Is on The Horizon ANNUAL REPORT 2022 - 2023 OPTHEA LIMITED Our cover Our lead drug candidate Sozinibercept (OPT-302) has the potential to become the first selective VEGF-C/D inhibitor for the treatment of wet AMD. Contents 0J About Opthea 02 Our Journey Sozinibercept Progressing in Global wet AMD Phase 3 Trials 04 Dr. Charles Wykoff 0୧ 08 Professor Timothy Jackson Chairman's Letter 10 CEO's Letter 12 13 Forward-looking Statements 14 Environmental, Social and Governance 20 Directors ...